Inhibition of matrix metalloproteinases (MMPs) as an approach to treat
ment of diseases such as cancer, arthritis and multiple sclerosis (MS)
is now an area of intense interest within the pharmaceutical industry
. This review summarises developments in the design and clinical evalu
ation of synthetic MMP inhibitors since the subject was last covered i
n this journal in 1996.